Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics’s CTX-112?
CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma.
CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma.
What's Your Reaction?
